ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1186 • ACR Convergence 2023

    Presence of Erosions Is Not a Risk Factor for the Development of Knee OA in a Hand OA Population: The Framingham OA Study

    Tine Vanhaverbeke1, Gabriela Rabasa2, Ruth Wittoek1, Ida Kristin Haugen3 and David Felson2, 1Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, 2Boston University, Boston, MA, 3Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: Osteoarthritis (OA) is a prevalent musculoskeletal disease and can affect multiple joint sites in one patient. Studies have shown an association between hand and…
  • Abstract Number: 1167 • ACR Convergence 2023

    Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)

    Yoshinobu Koyama1, Yoshiharu Sato2, Yu Nakai3 and Moe Tokunaga(Sakamoto)3, 1Japanese Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc, Tokyo, Japan, 3Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan

    Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…
  • Abstract Number: 1198 • ACR Convergence 2023

    Bicycling Is Not Associated with New Knee Pain or Disease Progression over 48 Months in Those with Knee Osteoarthritis: Data from the Osteoarthritis Initiative

    Colin McLaughlin1, Grace Lo1, Jeffrey Driban2, Timothy McAlindon3, Andrea Kriska4, Bonnie Rockette-Wagner4, Marc Hochberg5, Michael Nevitt6, Kent Kwoh7 and Charles Eaton8, 1Baylor College of Medicine, Houston, TX, 2Tufts Medical Center, Westborough, MA, 3Tufts Medical Center, Arlington, MA, 4University of Pittsburgh, Pittsburgh, PA, 5University of Maryland School of Medicine, Baltimore, MD, 6University of California San Francisco, Orinda, CA, 7University of Arizona, Tucson, AZ, 8Brown University, Pawtucket, RI

    Background/Purpose: Bicycling is viewed as a non-weight bearing exercise and is often recommended as a preferred exercise for those with knee osteoarthritis (OA).However, there is…
  • Abstract Number: 1017 • ACR Convergence 2023

    Cross Country Differences in b/tsDMARD Prescription Behavior: Associations Between Socioeconomics, Real World b/tsDMARD Use and Disease Outcomes

    Isabell Nevins1, Delphine COURVOISIER2, Axel Finckh3, Ruth Fritsch-Stork4, Dan Nordstrom5, Ana Maria Rodrigues6, Stefan Dinescu7, Alvaro Garcia8, Mert Oztas9, Ziga Rotar10, Karen Salomon11, Arvind Chopra12, David Vega Morales13, Marieke De Buck14, Denis Choquette15, Richard Conway16, Florenzo Iannone17, CF Allaart18, Thomas Huizinga18, Kim Lauper19 and Sytske Anne Bergstra18, 1Leiden University Medical Center, Amsterdam, Netherlands, 2Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, 3HUG, Geneva, Switzerland, 4Medical Health center Mariahilf and Sigmund Freud Private University, Utrecht, Netherlands, 5Helsinki University Hospital, Helsinki, Finland, 6Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, 7University of Medicine and Pharmacy of Craiova, Craiova, Romania, 8University Hospital del Tajo, Madrid, Spain, 9Istanbul University-Cerrahpasa, Istanbul, Turkey, 10University Medical Centre Ljubljana, Ljubljana, Slovenia, 11University of Massachusetts Medical School, Shrewsbury, MA, 12Center for Rheumatic Diseases, Pune, India, 13ROCHE, Ciudad de México, Mexico, 14Haaglanden Medisch Centrum, Den Haag, Netherlands, 15Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, 16Trinity College Dublin, Dublin, Ireland, 17Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, 18Leiden University Medical Center, Leiden, Netherlands, 19Geneva University Hospitals, Genève, Switzerland

    Background/Purpose: The development of biologic and targeted synthetic (b/ts)DMARDs contributed to improved treatment outcomes in rheumatoid arthritis (RA). However, high medication costs may limit their…
  • Abstract Number: 1144 • ACR Convergence 2023

    Deucravacitinib in Plaque Psoriasis: Maintenance of Response over 3 Years

    Bruce Strober1, Howard Sofen2, Shinichi Imafuku3, Carle Paul4, Melinda Gooderham5, Lynda Spelman6, Seong Jun Seo7, Thierry Passeron8, Renata M. Kisa9, Victoria Berger9, Eleni Vritzali10, Kim Hoyt9, Matthew J. Colombo9, Subhashis Banerjee9, Matthias Augustin11, Linda Stein Gold12, Andrew Alexis13, Diamant Thaçi14, Andrew Blauvelt15 and Mark Lebwohl16, 1Yale University, New Haven, CT, 2University of California Los Angeles School of Medicine and Dermatology Research Associates, Los Angeles, CA, 3Fukuoka University Faculty of Medicine, Fukuoka, Japan, 4Toulouse University and CHU, Toulouse, France, 5SKiN Centre for Dermatology, Ontario, Canada, 6Veracity Clinical Research, Brisbane, Australia, 7Chung-Ang University Hospital, Seoul, South Korea, 8Université Côte d’Azur, University Hospital of Nice, Nice, France, 9Bristol Myers Squibb, Princeton, NJ, 10Bayer, Sissach, Switzerland, 11Institute of Health Care Research in Dermatology and Nursing, Hamburg, Germany, 12Henry Ford Health System, MI, 13Weill Cornell Medicine, New York, NY, 14Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 15Oregon Medical Research Center, Portland, OR, 16Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of adults with plaque psoriasis. Deucravacitinib…
  • Abstract Number: 0327 • ACR Convergence 2023

    Self-management Strategies and Self-efficacy in Patients Living with Inflammatory Arthritis: Findings from a Quality Improvement Project in a Tertiary Centre

    Saadia Sasha Ali1, Karafotias Ioasaf2, Bechman Katie3, Andrew Rutherford4, Sophia Steer3 and Elena Nikiphorou3, 1King's College Hospital, Epsom, United Kingdom, 2King's College Hospital, London, United Kingdom, 3King's College London, London, United Kingdom, 4King's College Hospital, London, United Kingdom

    Background/Purpose: The 2021 EULAR guidelines on self-management have made recommendations (rec) to aid with the implementation of self-management strategies in inflammatory arthritis (IA) (1). Their…
  • Abstract Number: 1143 • ACR Convergence 2023

    Nationwide Analysis of Adult-Onset Still’s Disease with and Without Hemophagocytic Lymphohistiocytosis

    Faria Sami1, Michael Manansala2, Shilpa Arora1 and Augustine Manadan2, 1John H. Stroger Jr. Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL

    Background/Purpose: Adult-Onset Still's Disease (AOSD) commonly manifests with fever, arthritis, rash, liver dysfunction, lymphadenopathy, and hematologic abnormalities. AOSD is also associated with Hemophagocytic Lymphohistiocytosis (HLH).…
  • Abstract Number: 1204 • ACR Convergence 2023

    Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies

    Maurice Flurie1, Monica Converse1, Christopher Parker2, Brian LaMoreaux3, Daniel Hernandez4, N. Lawrence Edwards5, Gary Ho1, Kristina Davidson6, E. Robert Wassman1, Christopher DeFelice1 and Maria Picone1, 1TREND Community, Philadelphia, PA, 2TREND Community, Austin, TX, 3Horizon Therapeutics, Deerfield, IL, 4Global Healthy Living Foundation, St. Johns, FL, 5University of Florida College of Medicine, Gainesville, FL, 6Horizon Therapeutics, Dublin, Ireland

    Background/Purpose: To comprehensively understand the impact of disease management strategies, it is essential to understand the patient perspective. Gout is a chronic inflammatory arthritis characterized…
  • Abstract Number: 1207 • ACR Convergence 2023

    Cardiovascular Mortality of Acute Myocardial Infraction and Acute Heart Failure Hospitalization in Rheumatic Diseases Patients Evaluation from the 2016-2020 National Inpatient Sample (NIS) Database

    Zi Ying Li1, Siyi Huang2, senay Gokcebel3 and Anthony Reginato4, 1Roger Williams Medical Center, Providence, RI, 2UCSF Fresno, Fresno, CA, 3School of Public Health | Brown University, Providence, RI, 4The Warren Alpert Medical School of Brown University, Providence, RI

    Background/Purpose: Rheumatic diseases such as rheumatoid arthritis (RA) and Systemic lupus erythematosus (SLE) were known for increased prevalence and risk of death from cardiovascular disease…
  • Abstract Number: 1016 • ACR Convergence 2023

    Cost-related Medication Burden for Patients with and Without Systemic Autoimmune Rheumatic Diseases

    Jeong Yee1, Candace Feldman1, Emily G. Oakes1, Jack Ellrodt1, May Choi2, Elizabeth Karlson1 and Karen Costenbader3, 1Brigham and Women's Hospital, Boston, MA, 2University of Calgary, Calgary, AB, Canada, 3Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Medication nonadherence is a challenging issue in the management of systemic autoimmune rheumatic diseases (SARDs), leading to poor clinical outcomes. Although it is complex…
  • Abstract Number: 1202 • ACR Convergence 2023

    Goal Concordant Patient-clinician Dyads Have Higher Odds of Communication Around Rheumatoid Arthritis Goals

    Jennifer Barton1, Danielle ZuZero2, Diego Molina Ochoa3, Rachel Matsumoto4 and Edward Yelin5, 1VA Portland Health Care System/OHSU, Portland, OR, 2National University of Natural Medicine, Portland, OR, 3University of Maryland School of Medicine, Baltimore, MD, 4VA Portland Health Care System, Portland, OR, 5University of California San Francisco, San Francisco, CA

    Background/Purpose: Goal concordance between patients with chronic disease and their clinicians is linked to improved outcomes, however, less is known about goal concordance and goal…
  • Abstract Number: 1169 • ACR Convergence 2023

    All-cause Mortality and Risk Factors for Death in a Large Multi-center Prospective Registry Cohort of Idiopathic Inflammatory Myositis in China

    Liying Peng1, Peng Yin2, Mucong Li3, Qian Wang4, Yanhong wang1, Shuang Zhou4, chanyuan wu4, Jiuliang zhao1, Dong xu5, Mengtao Li3 and xiaofeng Zeng4, 1Peking Union Medical College, Beijing, China, 2Chinese Center for Disease Control and Prevention, Beijing, China, 3Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 4Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 5Peking Union Medical College Hospital, Beijing, China

    Background/Purpose: Our study depicted the mortality and independent risk factors of IIM patients in a large multi-center prospective registry cohort in China. Methods: Patients registered…
  • Abstract Number: 1161 • ACR Convergence 2023

    Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models

    Léa Debrut1, Margherita Giannini2, Céline Keime1, Daniela Rovito1, Béatrice Lannes3, Anne-Laure Charles4, Daniel Metzger1, Bernard Geny5, Gilles Laverny1 and Alain Meyer6, 1Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France, 2Nouvel Hopital Civil, Strasbourg, Strasbourg, France, 3Hôpital de Hautepierre - Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 4UR3072, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Strasbourg, France, 5Nouvel Hôpital Civil, Strasbourg, France, 6Hôpitaux Universitaires de Strasbourg, Strasbourg, France

    Background/Purpose: Dermatomyositis (DM) is an autoimmune myopathy responsible for muscle weakness associated with decreased quality of life and increased mortality. DM muscular histology is characterized…
  • Abstract Number: 1051 • ACR Convergence 2023

    Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis

    sibel aydin1, seyyid acikgoz2, Ummugulsum Oguz3, antonio Vieira4, patrick Leclerc4, Suharsh Shah4, Lihi Eder5 and Gurjit S Kaeley6, 1University of Ottawa - Ottawa, Ottawa, ON, Canada, 2University of Ottawa, Rheumatology, Ottawa, ON, Canada, 3University of Ottawa, Ottawa, ON, Canada, 4Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada, 5Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 6University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL

    Background/Purpose: Ultrasonography (US) has experienced a rapid evolution in rheumatology. Despite many advantages being shown repeatedly, several barriers persist and stand in the way of…
  • Abstract Number: 1046 • ACR Convergence 2023

    The Level of RF or Anti-CCP Antibody Affect Ultrasound Synovial Findings in Patients with Rheumatoid Arthritis?

    Tadashi Okano1, Kenji Mamoto1, Yutaro Yamada1, Shohei Anno2, Yuka Domae1, Shingo Washida1, Asami Yagami1, Yuko Yoshida1, Tatsuya Koike3 and Hiroaki Nakamura1, 1Osaka Metropolitan University, Osaka, Japan, 2Yodogawa Christian Hospital, Osaka, Japan, 3Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan

    Background/Purpose: Positive for auto-antibodies such as rheumatoid factor (RF) and anti-citrullinated peptide antibodies (CCP) or having high autoantibody titers is associated with the progression of…
  • « Previous Page
  • 1
  • …
  • 243
  • 244
  • 245
  • 246
  • 247
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology